An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups (Q84729221)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 August 2011

Language	Label	Description	Also known as
English	An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups	scientific article published on 07 August 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Valerian B Pinto

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Elizabeth E Moran

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Francisco Cruz

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Xin-Ming Wang

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Arthur Fridman

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Wendell D Zollinger

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Craig T Przysiecki

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Robert Burden

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

7 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

44

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

7752-7758

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Review of meningococcal group B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

A universal vaccine for serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Serotype-specific problems associated with pneumococcal conjugate vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Improved methods for producing outer membrane vesicles in Gram-negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

Cell envelope and shape of Escherichia coli: multiple mutants missing the outer membrane lipoprotein and other major outer membrane proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.124

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.07.124

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21827811%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84729221&oldid=2099877343"